In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia
Authors:
Open Access
- 28 April 2022
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 39 (5) , 837-850
Abstract
Purpose: Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1A agonist activity currently in clinical development for the treatment of schizophrenia. The objectives of the current study were to characterize the in vitro ADME properties, preclinical PK, and to evaluate the DDI potential of ulotaront and its major metabolite SEP-383103. Methods: Solubility, permeability, plasma protein binding, CYP inhibition and induction, transporter inhibition and uptake studies were conducted in vitro. Phenotyping studies were conducted using recombinant human CYPs and FMOs, human liver microsomes and human liver homogenates. Preclinical plasma and brain pharmacokinetics were determined after a single intraperitoneal, intravenous, and oral administration of ulotaront. Results: Ulotaront is a compound of high solubility, high permeability, and low binding to plasma proteins. Ulotaront metabolism is mediated via both NADPH-dependent and NADPH-independent pathways, with CYP2D6 as the major metabolizing enzyme. Ulotaront is an inducer of CYP2B6, and an inhibitor of CYP2D6, OCT1 and OCT2, while SEP-383103 is neither a CYP inducer nor a potent inhibitor of CYPs and human transporters. Ulotaront exhibits rapid absorption, greater than 70% bioavailability, approximately 3.5 L/kg volume of distribution, 1.5-4 h half-life, 12-43 ml/min/kg clearance, and good penetration across the blood–brain barrier in preclinical species. Conclusions: Ulotaront has been designated as a BCS1 compound by US FDA. The ability of ulotaront to penetrate the blood–brain barrier for CNS targeting has been demonstrated in mice and rats. The potential for ulotaront and SEP-383103 to act as perpetrators of CYP and transporter-mediated DDIs is predicted to be remote.Keywords
This publication has 27 references indexed in Scilit:
- Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo EvaluationDrug Metabolism and Disposition, 2016
- Glyceollin Effects on MRP2 and BCRP in Caco-2 Cells, and Implications for Metabolic and Transport InteractionsJournal of Pharmaceutical Sciences, 2016
- The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of MetforminClinical Pharmacokinetics, 2015
- The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersClinical Pharmacokinetics, 2015
- Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady statePharmacogenetics and Genomics, 2013
- Evidence for Substrate-Dependent Inhibition Profiles for Human Liver Aldehyde OxidaseDrug Metabolism and Disposition, 2013
- Profiling of a Prescription Drug Library for Potential Renal Drug–Drug Interactions Mediated by the Organic Cation Transporter 2Journal of Medicinal Chemistry, 2011
- PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κBCancer Chemotherapy and Pharmacology, 2009
- Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metforminPharmacogenetics and Genomics, 2009
- Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquineEuropean Journal of Clinical Pharmacology, 1996